Discover
APGE
Apogee Therapeutics, Inc.
134.20
4 x 134.18
1 x 134.19
bid
ask
+
0.00
0.00%
15 @ 08:02 AM
134.00 -0.20 (0.15%)
| Ytd | 77.80% | |
| 1y | 243.13% |
day range
34.34
52 week range
134.35
| Open | Prev Close | 134.20 | Low | High | Mkt Cap | 8.30B | |||
| Vol | 0.00 | Avg Vol | 2.56M | EPS | -4.33 | P/E | -30.99 | Forward P/E | -25.76 |
| Beta | 0.32 | Short Ratio | 0.94 | Inst. Own | 109.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 104.42 | 200-d Avg | 79.40 | 1yr Est | 130.53 |
| Income Statement | |||
| Operating Expenses | 82.77M | ||
| Research and Development Expense | 60.82M | ||
| Selling, General and Administrative Expense | 21.95M | ||
| Operating Income | -82.77M | ||
| Income Tax Expense | 79.00K | ||
| Net Income | -74.11M | ||
| Net Income Common Stock | -74.11M | ||
| Net Income Common Stock (USD) | -74.11M | ||
| Consolidated Income | -74.11M | ||
| Earnings per Basic Share | -1.06 | ||
| Earnings per Basic Share (USD) | -1.06 | ||
| Earnings per Diluted Share | -1.06 | ||
| Earning Before Interest & Taxes (EBIT) | -74.03M | ||
| Earning Before Interest & Taxes (USD) | -74.03M | ||
| Weighted Average Shares | 69.67M | ||
| Weighted Average Shares Diluted | 69.67M | ||
| Balance Sheet | |||
| Cash and Equivalents | 451.80M | ||
| Cash and Equivalents (USD) | 451.80M | ||
| Investments | 806.44M | ||
| Investments Current | 608.09M | ||
| Investments Non-Current | 198.35M | ||
| Current Assets | 1.07B | ||
| Property, Plant & Equipment Net | 12.99M | ||
| Total Assets | 1.29B | ||
| Debt Current | 3.14M | ||
| Total Debt | 8.05M | ||
| Current Liabilities | 32.95M | ||
| Debt Non-Current | 4.91M | ||
| Total Liabilities | 37.86M | ||
| Accumulated Retained Earnings (Deficit) | -635.87M | ||
| Accumulated Other Comprehensive Income | -749.00K | ||
| Shareholders Equity | 1.26B | ||
| Shareholders Equity (USD) | 1.26B | ||
| Assets Non-Current | 219.86M | ||
| Total Debt (USD) | 8.05M | ||
| Liabilities Non-Current | 4.91M | ||
| Trade and Non-Trade Payables | 1.24M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.39M | ||
| Net Cash Flow from Financing | 411.17M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 320.25M | ||
| Issuance (Purchase) of Equity Shares | 411.17M | ||
| Net Cash Flow from Investing | -35.35M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -35.35M | ||
| Net Cash Flow from Operations | -55.57M | ||
| Share Based Compensation | 17.16M | ||